Proteomics International Laboratories (ASX:PIQ) is a wholly owned subsidiary and trading name of PILL, a medical technology company at the forefront of predictive diagnostics and bioanalytical services. The Company specialises in the area of proteomics - the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) announced that the US Centers for Medicare & Medicaid Services has published its final determination of the national reimbursement price for the next-generation Promarker(R)D test system, the predictive test for diabetic kidney disease.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) announced that its majority owned subsidiary OxiDx Pty Ltd will today present groundbreaking performance data showing that Thoroughbred horses racing without oxidative stress were 76% more likely to place and 49% more likely to win.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, provided the Chair's Address and Company Presentation to be presented at the Company's Annual General Meeting.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) released a copy of the presentation to be provided by Dr Richard Lipscombe to attendees of the Bell Potter Healthcare Conference, a virtual event being held 18-20 November 2025.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) announced that its cash reserves have been further strengthened by the receipt of $2.2 million in research and development tax incentive for the 2024-25 financial year.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) announced it has been awarded a $500,000 grant from the Western Australian Government to accelerate the commercialisation of its world-first blood test for endometriosis, a condition affecting one in nine women globally.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) Managing Director Dr. Richard Lipscombe is interviewed about the most recent Quarterly Report and the pipeline of precision diagnostic tests in commercialisation phase.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, announced the following update on its business activities for the three months to 30 September 2025 and subsequent to the period end.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, is pleased to announce it has expanded its collaborative research agreement with the University of Melbourne and the Royal Women's Hospital.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, is pleased to announce the appointment of Ms Vicki Robinson to its Board as an independent non-executive director, effective 14 October 2025.
Correction - Notice of Extraordinary General Meeting/Proxy
Notice of Extraordinary General Meeting/Proxy Form
Investor Presentation - JMM Biotech Forum
Interim Financial Report and Appendix 4D
